BeOne Medicines AG (ONC) Stock AnalysisONCBeOne Medicines AG

BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others. It operates in the Healthcare sector.

Beigene, Ltd. (ONC) is a good buy right now due to its strong financial performance and positive catalysts. The current price is $377.63, with a gross margin of 89.76% in Q2 2026, indicating robust profitability. Additionally, analysts have set a price target range between $370 and $459, suggesting a potential upside of 10% to 22% from the current price. However, a significant risk is the hedge fund selling activity, which has increased by 7307.41% over the last quarter, indicating potential bearish sentiment among institutional investors.